Last reviewed: May 29, 2026 Last updated: May 29, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Patients combining GLP-1 with other treatments Some patients explore combining GLP-1 medications with other supplements or treatments
PDA meets none of the three criteria required for legal 503A compounding: no USP monograph, not a component of any FDA-approved drug, and not on the 503A bulks list, which BPC-157 has been recommended for but not added to
Abnormalities of mucosal serotonin metabolism and 5-HT3 receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron
Research indicates that topical GHK-Cu can support regulation of skin tone by promoting collagen and elastin synthesis and modulating inflammatory responses
